Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R3R01 · 1 trial · 1 indication
Urinary albumin-to-creatinine ratio (UACR) (Change from baseline to end of treatment at 12 weeks (84 days).
| Arm | Type | Description |
|---|---|---|
| R3R01 | EXPERIMENTAL | R3R01 oral tablet (200 mg twice daily) for 12 weeks |
| Placebo | PLACEBO_COMPARATOR | Placebo oral tablet twice daily for 12 weeks |
| Name | Type | Description |
|---|---|---|
| R3R01 | DRUG | R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information. |
| Placebo | DRUG | Please refer to arm/group description for further information. |
Inclusion Criteria: 1. Adults (above 18 years of age) with controlled type 2 diabetes (hemoglobin A1c less than 10.5%). 2. Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration. 3. Titrated to the maximal dose or maximal tolerated dose of renin-angiotens...